AL AMYLOIDOSIS

This study tests whether combining two drugs, teclistamab and daratumumab, can help people newly diagnosed with both multiple myeloma and AL amyloidosis. About 30 adults will receive the treatment for up to 2 years. The goal is to see if the combo improves survival without the di…

This early-phase study tests a personalized cell therapy (CAR-T cells) in 30 adults with relapsed or hard-to-treat light chain amyloidosis, a rare disease where abnormal proteins damage organs. The treatment targets BCMA on harmful plasma cells to reduce protein buildup. The main…

This study tests whether taking daratumumab for a longer time after initial treatment helps people with AL amyloidosis live longer without the disease coming back. About 96 adults who have already responded to daratumumab will be assigned to either shorter or longer maintenance t…

This study tests an experimental drug called teclistamab in 30 adults with AL amyloidosis, a rare disease where abnormal proteins damage organs. Participants have already received prior treatment. The goal is to see if teclistamab can improve blood markers and control the disease…

This study tests a drug called elranatamab in people with AL amyloidosis that has come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can reduce abnormal protein levels. About 49 adults will take part in this early-phase trial.

This study tests a drug called belantamab mafodotin in people with a rare blood disease called AL amyloidosis that has come back or not responded to other treatments. The goal is to find the safest and most effective dose. The study has two parts: first, different doses are teste…

This study tests a personalized approach for people with AL amyloidosis who have a specific genetic marker (t(11;14)). Participants start with a standard three-drug combo (daratumumab, bortezomib, dexamethasone). If they respond quickly, they continue that regimen; if not, they s…

This study compares two treatment plans for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. One group gets chemotherapy followed by a stem cell transplant; the other gets chemotherapy alone. The goal is to see which approach bette…

This study creates a large registry of 5,000 people with AL amyloidosis to observe how the disease progresses and how treatments affect it over time. Participants must be newly diagnosed or have past data available, and they continue their usual care. No experimental treatment is…

This study is creating a biobank and data registry for people with amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will collect blood, urine, tissue samples, and medical information from 505 participants over time. The goal is to store these ma…

This study looks at how a specific sugar change (N-glycosylation) on abnormal proteins might cause AL amyloidosis, a rare disease where proteins build up and damage organs. Researchers will analyze blood and bone marrow samples from 100 adults with related conditions to better un…

This study is creating a database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients access to expert consultations and information about su…

This study is creating a large European registry of 400 newly diagnosed AL amyloidosis patients. Researchers will collect medical data and blood samples to study the disease using advanced technology. The goal is to better understand how AL amyloidosis develops and progresses, wh…

This study looks at how a specific gene (IGLV1-44) leads to two rare diseases: AL amyloidosis and POEMS syndrome. Researchers will analyze blood and bone marrow samples from 100 adults with these conditions or multiple myeloma. The goal is to find unique gene patterns that could …

This study is creating a network of hospitals in Italy to find and treat AL amyloidosis earlier. Researchers will screen people with certain blood conditions (MGUS or smoldering myeloma) using special tests. The goal is to speed up diagnosis, connect patients to the right care, a…